Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03807739 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03807739 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 38 participants.
The verdict
NCT03807739, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a two-part study to determine the relative bioavailability of two different prototype capsules of GDC-0134 to that of an existing reference capsule of GDC-0134 under both fed and fasted conditions. The study is open to healthy female participants of non-childbearing potential.
Interventions
- DRUG GDC-0134 F09 Formulation
- DRUG GDC-0134 F15 Formulation
- DRUG GDC-0134 F16 Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03807739
The ClinicalTrials.gov registry entry for NCT03807739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GDC-0134 F09 Formulation is the first listed.
NCT03807739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03807739 about?
NCT03807739 is a clinical study titled "A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential". This is a two-part study to determine the relative bioavailability of two different prototype capsules of GDC-0134 to that of an existing reference capsule of GDC-0134 under both fed and fasted conditions. The study is open to healthy female participants of non-childbearing potential.
What is the current status of trial NCT03807739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2019-02-01. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT03807739?
The interventions under investigation include: GDC-0134 F09 Formulation (DRUG), GDC-0134 F15 Formulation (DRUG), GDC-0134 F16 Formulation (DRUG).
Who is sponsoring clinical trial NCT03807739?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.